Back to Search
ANDREW SEIDMAN, MD
MD
Medical Oncology Physician
NPI: 1578534335IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
177558(NY)
Education
OTHER
Class of 1985
Research & Publications (20)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
PMID 18375893·J Clin Oncol·2008
3-trial
Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
PMID 16596138·Nat Clin Pract Oncol·2006
3-trial
Systemic treatment of breast cancer. Two decades of progress.
PMID 16986346·Oncology (Williston Park)·2006
6-review
Current status of dose-dense chemotherapy for breast cancer.
PMID 16273358·Cancer Chemother Pharmacol·2005
6-review
Gemcitabine and docetaxel in metastatic breast cancer.
PMID 15685820·Oncology (Williston Park)·2004
6-review
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
PMID 14768399·Oncology (Williston Park)·2003
6-review
Monotherapy options in the management of metastatic breast cancer.
PMID 12722018·Semin Oncol·2003
6-review
Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
PMID 12454313·Oncologist·2002
8-other
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
PMID 12454316·Oncologist·2002
6-review
Cardiac dysfunction in the trastuzumab clinical trials experience.
PMID 11870163·J Clin Oncol·2002
3-trial
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
PMID 11352950·J Clin Oncol·2001
3-trial
The evolving role of gemcitabine in the management of breast cancer.
PMID 11340369·Oncology·2001
6-review
Gemcitabine as single-agent therapy in the management of advanced breast cancer.
PMID 11252882·Oncology (Williston Park)·2001
6-review
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects.
PMID 19253021·J Cancer Res Clin Oncol·2009
3-trial
Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
PMID 19596644·Clin Breast Cancer·2009
6-review
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
PMID 18323546·J Clin Oncol·2008
3-trial
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
PMID 18509177·J Clin Oncol·2008
8-other
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
PMID 18650151·Clin Breast Cancer·2008
6-review
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
PMID 19047117·Clin Cancer Res·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1578534335
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile